|Bid||12.60 x 100|
|Ask||20.55 x 300|
|Day's Range||15.30 - 15.55|
|52 Week Range||10.75 - 20.50|
|PE Ratio (TTM)||21.86|
|Dividend & Yield||0.50 (3.27%)|
|1y Target Est||N/A|
The U.S. health regulator on Thursday raised concerns about Meridian Bioscience Inc's facility that manufactures lead testing devices, nearly two months after the regulator warned that the tests may underestimate lead levels in blood. The Food and Drug Administration said it had issued Meridian unit, Magellan Diagnostics, a Form 483 for its North Billerica, Massachusetts-based facility, which manufactures the devices. Magellan's devices are the only lead testing products cleared by the FDA and account for about half of all lead tests in the United States.
The U.S. Food and Drug Administration on Thursday raised concerns about Meridian Bioscience Inc's facility that manufactures its testing device nearly two months after the regulator warned the tests underestimate lead levels in blood. The FDA issued a Form 483 to Magellan Diagnostics, which was bought by Meridian Bioscience in 2016 for $66 million, noting that the design validation does not ensure the device conforms to defined user needs. In May, the regulator warned laboratories and healthcare professionals not to use any lead testing device made by the company to test blood drawn from veins.
Categories: ETFs Yahoo FinanceClick here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Meridian Bioscience, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving ... Read more (Read more...)